ISX and lung cancer: Four potential lysine acetylation sites on BRD4 [289 (AC2), 291(AC1), 329 (AC3), and 332 (AC4)] were developed and expressed to examine the impact of the ISX–BRD4 complex on EMT in lung cancer cells (Fig 4A and B).